Although CD133 is known as a stem-cell marker, the results of previous studies, as well as the present study, indicate that both CD133+ and CD133− cells can generate tumor growth, suggesting that CD133 might not be an absolute biomarker for cancer stem cells in colon cancer. This evidence concerns the gene PROM1 and colonic neoplasm.